SRPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SRPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sarepta Therapeutics's Enterprise Value is $10,707 Mil. Sarepta Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-498 Mil. Therefore, Sarepta Therapeutics's EV-to-EBIT ratio for today is -21.50.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Sarepta Therapeutics's Enterprise Value is $10,707 Mil. Sarepta Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-454 Mil. Therefore, Sarepta Therapeutics's EV-to-EBITDA ratio for today is -23.60.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Sarepta Therapeutics's Enterprise Value is $10,707 Mil. Sarepta Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,243 Mil. Therefore, Sarepta Therapeutics's EV-to-Revenue ratio for today is 8.61.
The historical data trend for Sarepta Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 9,306.73 | 12,666.81 | 6,883.36 | 11,024.56 | 8,759.12 |
Sarepta Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Enterprise Value | Get a 7-Day Free Trial | 11,024.56 | 12,243.62 | 10,185.65 | 10,976.57 | 8,759.12 |
For the Biotechnology subindustry, Sarepta Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Sarepta Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 9038.557474 | + | 0 | + | 1273.48 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 123.328 | + | 0 | - | 1676.25 |
= | 8,759 |
Sarepta Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as
Enterprise Value (Q: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 9038.557474 | + | 0 | + | 1273.48 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 123.328 | + | 0 | - | 1676.25 |
= | 8,759 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics (NAS:SRPT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Sarepta Therapeutics's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 10707.272 | / | -498.088 | |
= | -21.50 |
Sarepta Therapeutics's current Enterprise Value is $10,707 Mil.
Sarepta Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-498 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Sarepta Therapeutics's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 10707.272 | / | -453.691 | |
= | -23.60 |
Sarepta Therapeutics's current Enterprise Value is $10,707 Mil.
Sarepta Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-454 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Sarepta Therapeutics's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 10707.272 | / | 1243.336 | |
= | 8.61 |
Sarepta Therapeutics's current Enterprise Value is $10,707 Mil.
Sarepta Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,243 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Sarepta Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Barry | director | 285 MARGALITA DRIVE, SAN RAFAEL CA 94901 |
Douglas S Ingram | director, officer: President & CEO | 2525 DUPONT DR, IRVINE CA 92612 |
Michael Andrew Chambers | director | 215 FIRST STREET, CAMBRIDGE MA 02142 |
Wigzell Hans Lennart Rudolf | director | OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935 |
Bilal Arif | officer: Chief Tech Ops Officer | 215 FIRST STREET, CAMBRIDGE MA 02129 |
Stephen Mayo | director | 2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
Kathryn Jean Boor | director | 3736 S. MAIN STREET, MARION NY 14505 |
Louise Rodino-klapac | officer: Chief Scientific Officer | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
M Kathleen Behrens | director | 6701 KAISER DRIVE, FREMONT CA 94555 |
Ryan Edward Brown | officer: SVP, General Counsel | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
Ian Michael Estepan | officer: Chief Financial Officer | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
Joseph Bratica | officer: Principal Financial Officer | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
David T Howton | officer: SVP, General Counsel | VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
John C Martin | director | 333 LAKESIDE DRIVE, FOSTER CITY X1 94404 |
Sandesh Mahatme | officer: Senior Vice President, CFO | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
From GuruFocus
By sperokesalga sperokesalga • 04-15-2023
By Business Wire • 06-22-2023
By Business Wire • 09-07-2023
By PRNewswire • 11-03-2023
By Business Wire • 11-02-2023
By Business Wire • 11-01-2023
By Business Wire • 07-03-2023
By Business Wire • 12-01-2023
By GuruFocus Research • 10-02-2023
By Business Wire Business Wire • 05-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.